This receptor is the molecular target of the thiazolidinedione (TZD) class of antidiabetic drugs, which include rosiglitazone and pioglitazone 4,5. PPAR-γ is prominently expressed in activated ...

Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either ...